Clinical Trial

12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated June 24, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a 12-month, single-arm, real-world study designed to evaluate the efficacy and safety of lecanemab (10 mg/kg administered every two weeks) in patients with early Alzheimer's disease, including mild cognitive impairment (MCI) due to AD or mild AD dementia, confirmed by amyloid-positive Aβ-PET scans. The study will enroll 80 participants, with both retrospective and prospective data collection.
Trial Details
NCT Number NCT07034222
Lead Sponsor Ruijin Hospital
Conditions Alzheimer's Disease(AD)
Enrollment 80 participants
Start Date 2024-02-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-24